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OBJECTIVES We sought to study whether patients with familial combined hyperlipidemia (FCH) or carotid
atherosclerosis have modified circulating solubilized Fas ligand (sFasL) levels, as well as the
potential modifications by atorvastatin. We also examined the effect of atorvastatin on FasL
expression and sFasL release in cytokine-stimulated cultured human endothelial cells (ECs).
BACKGROUND In normal situations, FasL is expressed in most cells, including ECs. Proinflammatory stimuli
can downregulate its expression in ECs and facilitate the vascular infiltration of inflammatory
cells.
METHODS We have measured sFasL plasma levels (by ELISA) in 58 patients with FCH, 14
normocholesterolemic patients with carotid atherosclerosis, and 15 healthy volunteers. We
analyzed FasL expression (by Western blot analysis) and sFasL release in cultured ECs
stimulated with tumor necrosis factor (TNF)-alpha.
RESULTS Solubilized FasL levels were decreased in hyperlipidemic patients (49 pg/ml), as compared
with healthy volunteers (123 pg/ml, p  0.0001). Patients were randomized to atorvastatin
(n  28) or bezafibrate (n  30) during 12 months. Atorvastatin treatment increased sFasL
concentrations (111 pg/ml, p  0.0001), reaching normal values. However, treatment with
bezafibrate only marginally affected sFasL (85 pg/ml, p  0.05). Solubilized FasL was also
diminished in patients with carotid atherosclerosis (39 pg/ml), and intensive treatment with
atorvastatin normalized sFasL levels (90 pg/ml, p  0.02). Finally, atorvastatin prevented the
diminution of FasL expression and sFasL release elicited by TNF-alpha in cultured ECs.
CONCLUSIONS Patients with FCH or carotid atherosclerosis have decreased circulating sFasL levels, probably
indicating endothelial dysfunction, but treatment with atorvastatin restored normal blood
levels. These data provide a novel effect of atorvastatin and add support for the well-known
anti-inflammatory properties of statins. (J Am Coll Cardiol 2004;43:1188–94) © 2004 by
the American College of Cardiology Foundationhe Fas-Fas ligand system is a representative pathway of tissues (2). The membrane-bound FasL is converted to a
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mpoptosis-signaling receptor molecules. The Fas ligand
FasL or CD95L) is a type II membrane protein that is
omologous to tumor necrosis factor (TNF)-alpha (1). The
as ligand induces apoptosis or programmed cell death
hen bound to its membrane receptor Fas (also known as
poptosis antigen-1 [APO-1] or CD95). Engagement of
asL promotes the trimerization of Fas and the formation
f a signaling complex of molecules linked by protein–
rotein interactions with the cytoplasmic portion of the
eceptor. Although the expression of FasL was originally
onsidered restricted to activated T lymphocytes and natural
iller cells, it has also been identified in several organs and
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onversion of membrane FasL to its solubilized form decreases
ts apoptotic activity, although sFasL retained its capacity to
nteract with Fas, and restoration of total cytotoxic activity has
een achieved both in vitro and in vivo by the addition of
ross-linking antibodies (4). Expression of FasL has been
lassically described to be induced during an immune-
nhanced response (5,6). However, the constitutive expression
f FasL has been linked to tissue-specific regulation of various
mmune processes. In this way, the expression of functional
asL by some tissues contributes to their immune-privileged
tatus by impairing survival of infiltrating leukocytes (7). Also,
ecent reports have demonstrated that endothelial cells (ECs)
xpress FasL constitutively and therefore regulate leukocyte
essel wall infiltration (8). Familial combined hyperlipidemia
FCH) is a common form of dyslipidemia characterized by
ncreased low-density lipoprotein (LDL) cholesterol and tri-
lyceride serum levels, usually associated with low concentra-
ions of high-density lipoprotein (HDL) cholesterol (9).
his lipid phenotype carries a high risk of premature coronary
rtery disease (10,11). Fibric acid derivatives and hydroxy-
ethylglutaryl-coenzyme A (HMG-CoA) reductase inhibi-ors (statins) are frequently used in combined hyperlipidemia
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April 7, 2004:1188–94 Circulating Fas Ligand and Atherosclerosis12). Large clinical trials have demonstrated that statins reduce
he risk of myocardial infarction and stroke (13). Increasing
vidence suggests that statins exert cardiovascular effects be-
ond the lowering of serum cholesterol levels (14).
Sustained hyperlipidemia is associated with subendothelial
ipoprotein deposits in atherosclerosis-prone areas of the vas-
ulature, triggering endothelial adhesion molecule expression
nd monocyte infiltration, probably in an attempt to remove
he lipid deposits. We hypothesized that if FasL expression in
ormal ECs regulates leukocyte infiltration, high cholesterol
evels would be associated with a decrease in FasL expression,
nd therefore sFasL would vary accordingly. We first studied
FasL levels in patients with FCH at baseline and 12 months
fter randomization to treatment with atorvastatin or bezafi-
rate, and we then compared them to a matched control
opulation. We also studied sFasL levels in patients with
linical atherosclerosis without marked hyperlipidemia and
valuated the effect of short-term, high-dose statin treatment
n sFasL. Finally, we assessed the in vitro effect of atorvastatin
n FasL expression and sFasL release in cytokine-stimulated
ultured human ECs.
ETHODS
atients with FCH. The hyperlipidemic population in-
luded 58 patients participating in the Atorvastatin versus
ezafibrato Mixed Hyperlipidemia (ATOMIX) trial, a one-
ear randomized, double-blinded, multicenter study of adult
atients with combined hyperlipidemia in which atorvastatin
nd bezafibrate therapies were compared (15). The character-
stics of the study population are shown in Table 1.
Patients were included in the trial if, after discontinuation
f any lipid-regulating drug, formal dietary counseling and
ood compliance with the prescribed diet, and a six-week
un-in period of placebo treatment, they had a mean (of 2
onsecutive analyses at weeks 4 and 2) triglyceride level
f 500 and 200 mg/dl, respectively, in addition to LDL
holesterol 250 and 190, 180, 160, or 135 mg/dl,
epending on the global risk status (low, moderate, high, or
resence of coronary heart disease, respectively), according
o the European Atherosclerosis Society (EAS) recommen-
ations (16). Patients were ineligible if they were pregnant
r nursing or had dysbetalipoproteinemia, chronic liver
Abbreviations and Acronyms
EC  endothelial cell
FCH  familial combined hyperlipidemia
GGPP  geranylgeranyl pyrophosphate
HDL  high-density lipoprotein
HMEC-1  human microvascular endothelial cell
HMG-CoA  hydroxymethylglutaryl-coenzyme A
LDL  low-density lipoprotein
PBST  phosphate-buffered saline containing 0.1%
Tween-20
sFasL  solubilized Fas ligand
TNF  tumor necrosis factorisease or hepatic dysfunction, nephrotic syndrome or renalnsufficiency, a body mass index 30 kg/m2, known hyper-
ensitivity to HMG-CoA reductase inhibitors or fibrates,
nd a weekly average consumption of more than 130 g of
lcohol. Patients with uncontrolled hypertension, hypothy-
oidism or uncontrolled type II diabetes mellitus were also
xcluded. Patients must not have had a myocardial infarc-
ion, angioplasty, severe or unstable angina pectoris, or any
ther cardiovascular event resulting in hospitalization dur-
ng the six months preceding the study. Drugs known to
ffect lipid levels or to interact with study medication were
ot allowed. Dietary compliance was assessed at baseline,
nd noncompliant patients were also excluded.
Patients were randomly assigned to receive a daily dose of
ither 10 mg atorvastatin or 400 mg bezafibrate. After 8 and 16
eeks of double-blinded treatment, the dose of atorvastatin
ould be doubled, according to the modified EAS LDL
holesterol target guidelines (LDL cholesterol175, 155, 135,
r 100 mg/dl for patients at low risk, moderate risk, high risk,
r with coronary heart disease, respectively) (16). At week 26,
f after two consecutive titrations, LDL cholesterol levels were
till above target, open-label colestipol (3 sachets of 5 g/day)
as recommended for the rest of the study in both arms. The
ipid values of randomized patients were kept unknown to both
he patient and the investigator until the end of the study.
The control population included 15 healthy adults
atched by age and gender.
atients with atherosclerotic carotid disease. Fourteen
ormocholesterolemic patients with carotid atherosclerosis
carotid stenosis 70%, as diagnosed by Doppler echocar-
iography) and without previous statin therapy were ran-
omized to receive 80 mg/day atorvastatin (n  7) or usual
are (n  7) during four to six weeks before they underwent
cheduled carotid endarterectomy at the Hospital Clı´nico
an Carlos, Madrid, Spain (Prof. J. Serrano). Written,
nformed consent was obtained from all patients before
nrollment. The study was approved by the Hospital’s
thical Committee, in accordance with the institutional
uidelines.
Patients were excluded from the trial if they were preg-
ant or nursing, had some inflammatory disease or tumor,
r had been treated with hypolipemic or anti-inflammatory
able 1. Characteristics of Hyperlipidemic Patients
Variable
Atorvastatin
Group
(n  28)
Bezafibrate
Group
(n  30) p Value
ge (yrs) 49.9  11 52.9  11 0.29
ody mass index (kg/m2) 27.7  2 27.4  2 0.56
ender 0.25
Men 24 (86%) 22 (73%)
Women 4 (14%) 8 (27%)
iabetic 2 (7%) 4 (13%) 0.44
moker 9 (32%) 10 (33%) 0.92
istory of CHD 8 (29%) 12 (40%) 0.36
amiliar history of CHD 5 (18%) 4 (13%) 0.63
ata are expressed as the mean value  SD or number (%) of patients.
CHD  coronary heart disease.
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Circulating Fas Ligand and Atherosclerosis April 7, 2004:1188–94rugs (except aspirin 325 mg/day) during the year pre-
eding the study. Patients must not have had a myocardial
nfarction, angioplasty, severe or unstable angina pectoris, or
ny other cardiovascular event resulting in hospitalization
uring the six months preceding the study.
aboratory determinations. Venous blood samples were
ollected in EDTA before the randomization visit and 6
nd 12 months later in patients with FCH and four to six
eeks later in patients with atherosclerotic carotid disease.
he whole serum samples were stored at 80°C until
nalysis was performed. Lipid determinations were done
sing standard techniques.
Serum concentrations of sFasL were determined in du-
licate with commercially available enzyme-linked immu-
osorbent assay kits (Diaclone Research, Besancon,
rance). A total of 100 l of serum samples was assayed in
arallel to known standard concentrations. Each assay was
alibrated using a sFasL standard curve. The minimum
etectable level of sFasL was 12 pg/ml. Intra- and interassay
oefficients of variation were 4.5% and 7.1%, respectively.
ndothelial cell culture. Human microvascular endothe-
ial cells (HMEC-1) were a gift from C. Caramelo, MD,
hD (Fundacio´n Jime´nez Dı´az, Madrid, Spain). Cells were
aintained in culture in MCDB-131 medium supple-
ented with 100 g/ml penicillin, 100 g/ml streptomycin,
0% decomplemented fetal calf serum, 10 ng/ml epidermal
rowth factor, and 1 g/ml hydrocortisone. Media were
eplaced every two to three days. At confluence, cells were
arvested for passaging with trypsin-EDTA. Cells between
assages 3 and 7 were used for the experiments. MCDB-
31 and fetal calf serum were obtained from Invitrogen,
ibco (Carlsbad, California). Penicillin, streptomycin, and
rypsin-EDTA were from BioWhitaker (Walkerswille,
aryland). Epidermal growth factor was from Invitrogen
nd hydrocortisone was from Sigma (St. Louis, Missouri).
n all in vitro experiments, the ECs were preincubated for
h with atorvastatin, mevalonate, or isoprenoids.
estern blot analysis. Cells from different experimental
onditions were collected, rinsed twice with cold phosphate-
uffered saline (PBS), pelleted, and resuspended in lysis buffer
ontaining 10% sodium dodecyl sulfate, glycerol, Tris hydro-
hloride, and water. Protein concentrations were calculated by
he bicinchoninic acid method (Pierce, Rockford, Illinois).
qual amounts of protein were loaded into 12% acrylamide
els and electrophoresed. The resolved proteins were trans-
able 2. Lipid Profile of Hyperlipidemic Patients
Atorvastatin
Basal 6 Months
otal cholesterol (mg/dl) 284  32 195  28*#
DL cholesterol (mg/dl) 194  28 116  27*#
riglycerides (mg/dl) 266  57 235  67†
DL cholesterol (mg/dl) 37  7 41  6‡#
torvastatin versus baseline: *p  0.0001, †p  0.001, ‡p  0.01. Bezafibrate versus
ata are presented as the mean value  SD.
HDL and LDL  high- and low-density lipoprotein, respectively.erred onto polyvininylidene fluoride membranes (Immobilon,
illipore, Billerica, Massachusetts). The nonspecific sites of
he membranes were blocked by incubation for 1 h at room
emperature in 7.5% nonfat dry milk powder in PBS contain-
ng 0.1% Tween-20 (PBST). The membranes were incubated
vernight at 4°C with rabbit anti-FasL polyclonal antibody
sc-834; Santa Cruz Biotechnology, Santa Cruz, California) or
onoclonal anti-alpha-tubulin (T5168; Sigma) in PBST con-
aining 5% nonfat dry milk. The membranes were washed with
BST and incubated for 1 h at room temperature with
orseradish peroxidase–conjugated secondary antibody (Am-
rsham, Buckinghamshire, United Kingdom) in PBST con-
aining 5% nonfat dry milk. After a PBST wash, they were
ncubated for 30 min in PBST containing 400 mm NaCl,
ollowed by detection with enhanced chemiluminescence
ECL kit, Amersham). Films were scanned on a densitometer
nd quantified using the ImageQuant Software (Molecular
ynamics, Sunnyvale, California).
tatistical analysis. We evaluated the effects of atorvastatin
nd bezafibrate in 58 patients in whom baseline, six-month,
nd 12-month blood samples were available. The normality of
esiduals was checked for each model, using the Shapiro-
ilks’ W test. All W statistics for sFasL models (at baseline
nd 6 and 12 months) were significant (p  0.001), and the
ypothesis of a normal distribution was rejected. The median
alues and 25th and 75th percentiles at baseline and changes
rom baseline were computed, and rank analysis of covariance
as performed to compare the effects of atorvastatin and
ezafibrate from baseline. The model included the effects due
o treatment and baseline sFasL as covariates. In addition, we
valuated the effects of atorvastatin or usual care in 14 patients
ith carotid atherosclerosis in whom baseline and four- to
ix-week blood samples were available.
Spearman correlation was used to make comparisons
etween the different parameters analyzed. The SAS version
.2 (Cary, North Carolina) was used for analysis.
For the in vitro studies, representative data from three or
our experiments are presented. To compare the group
ean values, analysis of variance and the Student-Newman-
euls test were used, as appropriate. A value of p  0.05
as considered to be statistically significant.
ESULTS
torvastatin, bezafibrate, and lipid profile in hyperlipid-
mic patients. Table 2 shows the changes in lipid variables
Bezafibrate
Months Basal 6 Months 12 Months
7  26*# 275  31 266  29¶ 256  26§
9  23*# 178  24 186  27 171  23¶
1  86* 297  78 184  66§ 202  85§
3  6* 38  8 49  7§ 48  7§
e: §p  0.0001, ¶p  0.01. Atorvastatin versus bezafibrate: #p  0.0001, p  0.01.12
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April 7, 2004:1188–94 Circulating Fas Ligand and Atherosclerosisor atorvastatin and bezafibrate at six and 12 months. At this
ime, atorvastatin treatment decreased total cholesterol (284
2 basal vs. 195 29 at 6 months and 197 26 at 12 months,
 0.0001), LDL cholesterol (194  29 basal vs. 116  27
t 6 months and 119  23 at 12 months, p  0.0001), and
riglycerides (266  57 basal vs. 235  67 at 6 months, p 
.0004, and 211  86 at 12 months, p  0.0001). On the
ther hand, treatment with bezafibrate led to a significant
eduction of total cholesterol (256  26 at 12 months, p 
.0001), LDL cholesterol (171  23 at 12 months, p 
.0014), triglycerides (297 57 basal vs. 184 66 at 6 months
nd 202  85 at 12 months, p  0.0001). Atorvastatin was
uperior to bezafibrate in reducing total cholesterol (p 
.0001) and LDL cholesterol (p  0.0001), and bezafibrate
as superior to atorvastatin in increasing HDL cholesterol (p
0.0001 at 6 months and p  0.0048 at 12 months).
evels of sFasL in hyperlipidemic patients. To explore
he association between hyperlipidemia and circulating
FasL, we measured plasma sFasL levels in 58 patients with
CH and 15 healthy volunteers. The average sFasL level in
ontrol subjects was 123 pg/ml, similar to that previously
eported (17). At baseline, hyperlipidemic patients showed a
ignificantly lower average sFasL concentration (49 pg/ml, p
0.0001 vs. control subjects) (Fig. 1).
oncentrations of sFasL in atorvastatin- or bezafibrate-
reated hyperlipidemic patients. We analyzed the effect of
ix and 12 months of treatment with atorvastatin or beza-
brate on sFasL levels in patients with combined hyperlip-
demia. The basal sFasL plasma level in the atorvastatin
roup (n  28) was 56 pg/ml (Fig. 2). The administration
f atorvastatin significantly increased sFasL levels at six
onths (88 pg/ml, p  0.0103 vs. basal) and 12 months
111 pg/ml, p  0.0001 vs. basal), reaching normal values,
ithout significant variations compared with healthy con-
rols. On the other hand, the basal sFasL plasma level in the
ezafibrate group (n  30) was 46.8 pg/ml, and treatment
uring six months had no effect on circulating sFasL (Fig.
). Only when the effect of 12 months of treatment was
igure 1. Effect of hyperlipidemia on solubilized Fas ligand (sFasL) levels.
epresentation of sFasL concentrations in healthy volunteers and hyper-
ipidemic patients. Data are expressed as median values.nalyzed did we note that bezafibrate increases sFasL levels t85.4 pg/ml, p 0.046). At baseline, sFasL plasma levels in
he atorvastatin and bezafibrate groups were statistically
imilar. As shown in Figure 3, treatment with atorvastatin
as superior to bezafibrate in normalizing sFasL levels at six
p  0.01) and 12 months (p  0.02). No statistical
ifferences were found between patients treated with and
hose without colestiramine after 12 months of treatment.
There was no correlation between different lipid variables
nd sFasL plasma levels at baseline or after 6 and 12 months
f treatment with atorvastatin (data not shown).
evels of sFasL in patients with carotid atherosclerosis.
o further analyze the effect of atorvastatin on sFasL levels,
4 normocholesterolemic patients without previous statin
herapy but with carotid atherosclerosis were randomized to
eceive 80 mg/day atorvastatin (n  7) or usual care (n  7)
uring four to six weeks before they underwent carotid
ndarterectomy (Table 3). Treatment with atorvastatin
educed total cholesterol (186  33 basal vs. 125  32 after
reatment, p 0.001) and LDL cholesterol (123 25 basal
s. 64  28 after treatment, p  0.05) (Table 4). In
ddition, we observed that patients with carotid stenosis had
educed sFasL levels (40 pg/ml), and that treatment with
torvastatin normalized sFasL concentrations, as compared
ith patients treated with usual care (90.7 vs. 48.3 pg/ml,
espectively; p  0.02) (Fig. 4). There was not any corre-
igure 2. Effect of atorvastatin or bezafibrate treatment on circulating
olubilized Fas ligand (sFasL) levels in patients with hyperlipidemia.
torvastatin treatment normalized sFasL levels in hyperlipidemic patients
t six (striped bars) and 12 months (solid bars). Open bars  baseline.
ata are expressed as median values. *p  0.0001 and †p  0.0005
ompared with healthy subjects.
igure 3. Changes in solubilized Fas ligand (sFasL) after treatment with
torvastatin (open bars) and bezafibrate (solid bars). Data are expressed as
he change in median value with respect to baseline.
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Circulating Fas Ligand and Atherosclerosis April 7, 2004:1188–94ation between different lipid variables and sFasL plasma
evels in patients with carotid atherosclerosis. On the whole,
hese data indicate that atorvastatin may normalize sFasL in
atients with early and late atherosclerosis.
ffect of atorvastatin on endothelial FasL. Finally, we
nalyzed the effect of atorvastatin on FasL expression and
FasL release in human cultured ECs. In accordance with
revious studies (8), treatment with TNF-alpha decreased
asL expression in ECs (Fig. 5). To study whether atorva-
tatin could normalize FasL expression decreased by TNF-
lpha, HMEC-1 cells were preincubated for 2 h with
torvastatin and then incubated in the presence of 25 ng/ml
NF-alpha. As shown in Figure 5A, atorvastatin prevented
he diminution of FasL protein expression in cultured ECs.
urthermore, atorvastatin also prevented the diminution of
FasL levels induced by TNF-alpha in the supernatant of
C cultures (5.6  2 [TNF-alpha] vs. 19.41  3 [TNF-
lpha plus 10 mol/l atorvastatin] pg/ml, p  0.05) (Figs.
B and 5C). These results indicate that atorvastatin can
egulate FasL expression and FasL release by ECs.
ffect of isoprenoids on endothelial FasL. Mevalonate is
he metabolite that is directly synthesized by HMG-CoA
eductase. We analyzed the effect of mevalonate on FasL
xpression. Endothelial cells were preincubated for 2 h with
torvastatin (10 mol/l) in the presence of mevalonate (100
mol/l) and then incubated with TNF-alpha (25 ng/ml)
uring 6 h. Mevalonate diminished FasL expression in the
resence of atorvastatin (Fig. 6A). Moreover, mevalonate also
ecreased sFasL levels in the supernatant of cultured ECs (Fig.
B).
Furthermore, we analyzed the importance of isoprenoids
elated to the mevalonate pathway in FasL expression, and
able 3. Characteristics of Patients With Carotid
therosclerosis
Variable
No Treatment
(n  7)
Atorvastatin
(n  7)
ge (yrs) 68.6  9 71.5  6
ender
Men 5 (71%) 5 (71%)
Women 2 (29%) 2 (29%)
iabetic 2 (29%) 2 (29%)
moker 1 (14%) 0
istory of CHD 6 (86%) 6 (86%)
ata are expressed as the mean value  SD or number (%) of patients.
CHD  coronary heart disease.
Table 4. Lipid Profile of Patients With Caroti
No Trea
Before
Total cholesterol (mg/dl) 209  64
LDL cholesterol (mg/dl) 143  52
Triglycerides (mg/dl) 143  52
HDL cholesterol (mg/dl) 43  13
Before versus after: *p  0.01 and †p  0.05. No treatment v
 SD.Abbreviations as in Table 2.e observed that geranylgeranyl pyrophosphate (GGPP-5,
mol/l), but not farnesyl pyrophospahte (FPP-5, mol/l),
educed FasL expression in the presence of atorvastatin
Fig. 6A). Only GGPP was able to decrease sFasL levels in
he supernatant of cultured ECs. These results indicate that
GPP, probably through geranylgeranylation of proteins,
an be involved in the regulation of FasL expression.
ISCUSSION
he Fas ligand is constitutively expressed on normal ECs and
ay exert an atheroprotective function through its ability to
nduce apoptosis in mononuclear cells attempting to invade the
essel wall in the absence of normal inflammatory stimuli (6).
n contrast, leukocytes express FasL only when activated.
hese cells are present in atherosclerotic lesions and contribute
o the progression of plaque formation (18).
Membrane-bound FasL is converted to a solubilized
orm by a matrix metalloproteinase-like enzyme. The rele-
ance of sFasL serum concentrations is indicated by an
ncrement of sFasL levels observed in natural killer lym-
homa (19) and rheumatic diseases (20). In addition, an
ncrement of sFasL has been shown in patients with
yocarditis (7) and in subjects with congestive heart failure
8), situations in which inflammatory cells are activated.
urthermore, Shimizu et al. (21) have recently reported that
FasL is increased in patients with myocardial infarction
nd unstable angina pectoris.
The Fas ligand expressed in ECs may contribute to the
ormal concentrations of circulating sFasL. In our study, we
bserved that sFasL is present in all healthy volunteers in
herosclerosis
t Atorvastatin
After Before After
72  41 186  33 125  32*‡
14  33 123  25 64  28†‡
33  42 144  50 100  47
37  9 42  9 41  10
torvastatin: ‡p  0.05. Data are presented as the mean value
igure 4. Effect of atorvastatin on circulating solubilized Fas ligand
sFasL) in patients with carotid atherosclerosis. Atorvastatin treatment
open bars) increased sFasL levels in patients with carotid atherosclerosis
t four to six weeks. Solid bars  no treatment. Data are expressed as
edian values.d At
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April 7, 2004:1188–94 Circulating Fas Ligand and Atherosclerosisoncentrations considered as normal (17). However, pa-
ients with FCH have a marked decrease in sFasL levels. It
s possible that the endothelial dysfunction occurring in
atients with hyperlipidemia may be responsible for this
nding, probably due to lesser endothelial synthesis and/or
elease into the blood. In contrast, increased levels of soluble
ellular adhesion molecules have been found in patients with
yperlipidemia (22), and it has been attributed to the
nflammation and activation of ECs (23). In this sense, it is
mportant to remember that inflammatory stimuli, such as
NF-alpha, may upregulate adhesion molecule expression
nd downregulate FasL expression in ECs (6). We now
how that treatment with atorvastatin prevents FasL down-
egulation induced by TNF-alpha in cultured ECs. More-
ver, atorvastatin normalized the release of sFasL by ECs in
he presence of TNF-alpha.
The lowering of cholesterol plasma levels by diet or drugs
igure 5. Effect of atorvastatin on Fas ligand (FasL) expression and solubi-
ized Fas ligand (sFasL) released by human cultured endothelial cells (ECs).
ndothelial cells were preincubated for 2 h with atorvastatin (Atv). (A)
estern blot showing the effect of atorvastatin on FasL expression in ECs. (B)
NF-alpha decreased sFasL release by ECs at 6 h. Treatment with atorva-
tatin normalized circulating sFasL levels in a dose-dependent manner. *p 
.05 vs. baseline; †p  0.05 vs. 25 ng/ml tumor necrosis factor (TNF)-alpha.
C) Treatment with atorvastatin (10 mol/l) prevented the diminution of
FasL induced by TNF-alpha (*p  0.05 vs. 25 ng/ml TNF-alpha).ownregulates adhesion molecule expression and reduces the pensity of inflammatory cells in atherosclerotic plaques (24).
he present measurements show that the changes in circulat-
ng sFasL reflect analogous effects of statins on ECs. This
uggests that statins may inhibit the recruitment of leukocytes
ssociated with hypercholesterolemia by increasing endothelial
asL expression. Our results also indicate that the normaliza-
ion of sFasL levels is not simply due to the reversal of
ypercholesterolemia, because we observed an analogous sFasL
ncrease in patients whose plasma cholesterol fell within the
ormal range. However, even in these patients, the increase in
FasL was accompanied by a highly significant further reduc-
ion of cholesterol levels. Moreover, although the cholesterol-
owering effect of atorvastatin was far more powerful than that
f bezafibrate, prolonged fibrate treatment also raised sFasL.
hus, future studies will have to establish whether the mech-
nism responsible for the increase in sFasL is truly independent
f cholesterol lowering.
Several cholesterol-independent effects of statins in vitro
ave been reported, such as the statin-induced upregulation of
ndothelial nitric oxide mediated by a decrease in GGPP
evels, an isoprenoid intermediate of the cholesterol synthesis
athway, and inhibition of the geranylgeranylation of Rho
igure 6. Effect of mevalonate (MVA) or isoprenoids on Fas ligand (FasL)
xpression and solubilized Fas ligand (sFasL) released by human cultured
ndothelial cells (ECs). Endothelial cells were preincubated for 2 h with
torvastatin (Atv), mevalonate, or isoprenoids and then 6 h with tumor
ecrosis factor (TNF)-alpha (25 ng/ml). (A) Western blot showing the
ffect of mevalonate, farnesyl pyrophosphate (FPP), or geranylgeranyl
yrophosphate (GGPP) on FasL expression in ECs. (B) Mevalonate and
GPP decreased sFasL release by ECs in the presence of atorvastatin (*p
0.05 vs. atorvastatin).roteins (25). In addition, other cholesterol-independent ef-
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uanosine triphosphatase, such as inhibition of the cell-cycle
rogression of vascular smooth muscle cells or the release of
issue plasminogen activator (26,27). In this sense, we also
oted that FasL expression is controlled by GGPP in human
Cs, indicating that isoprenoids can contribute to its regula-
ion.
The normalization of sFasL by atorvastatin may contrib-
te to a decrease in the influx of inflammatory cells to the
essel wall and prevent the progression of plaque formation.
n this sense, FasL-deficient mice display enhanced leuko-
yte infiltration and intima hyperplasia (28), and FasL gene
ransfer to the vessel wall can effectively inhibit the vessel
esion formation (29).
onclusions. The present study shows, for the first time,
hat patients with FCH have low circulating sFasL levels, and
hat treatment with atorvastatin normalizes them. Moreover, it
rovides an additional explanation by which hyperlipidemia
ay contribute to the development of atherosclerotic lesions:
igh lipids might alter the regulation of inflammatory cells
xtravasation. In addition, atorvastatin also normalized sFasL
evels in normocholesterolemic patients with carotid stenosis.
urthermore, atorvastatin prevented FasL downregulation and
FasL release in cytokine-stimulated ECs. However, the
echanisms by which hyperlipidemia or carotid atherosclerosis
educe sFasL levels and atorvastatin normalizes them remain to
e elucidated.
Further studies are needed to assess whether the
ecrease in sFasL levels constitutes a marker of endothe-
ial dysfunction. Experiments to explore this possibility
re currently underway in our laboratory in patients with
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